FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213065184> ?p ?o ?g. }

• W4213065184 endingPage "871" @default.
• W4213065184 startingPage "858" @default.
• W4213065184 abstract "This trial aimed to determine the efficacy of leucine and/or perindopril in improving physical function in older people with sarcopenia.Placebo-controlled, parallel group, double-blind, randomized two-by-two factorial trial. We recruited adults aged ≥ 70 years with sarcopenia, defined as low gait speed (<0.8 m/s on 4 m walk) and/or low handgrip strength (women < 20 kg, men < 30 kg) plus low muscle mass (using sex and body mass index category-specific thresholds derived from normative UK BioBank data) from 14 UK centres. Eligible participants were randomized to perindopril 4 mg or placebo, and to oral leucine powder 2.5 g or placebo thrice daily. The primary outcome was the between-group difference in the short physical performance battery (SPPB) score over 12-month follow-up by repeated-measures mixed models. Results were combined with existing systematic reviews using random-effects meta-analysis to derive summary estimates of treatment efficacy.We screened 320 people and randomized 145 participants compared with an original target of 440 participants. For perindopril [n = 73, mean age 79 (SD 6), female sex 39 (53%), mean SPPB 7.1 (SD 2.3)] versus no perindopril [n = 72, mean age 79 (SD 6), female sex 39 (54%), mean SPPB 6.9 (SD 2.4)], median adherence to perindopril was lower (76% vs. 96%; P < 0.001). Perindopril did not improve the primary outcome [adjusted treatment effect -0.1 points (95%CI -1.2 to 1.0), P = 0.89]. No significant treatment benefit was seen for any secondary outcome including muscle mass [adjusted treatment effect -0.4 kg (95%CI -1.1 to 0.3), P = 0.27]. More adverse events occurred in the perindopril group (218 vs. 165), but falls rates were similar. For leucine [n = 72, mean age 78 (SD 6), female sex 38 (53%), mean SPPB 7.0 (SD 2.1)] versus no leucine [n = 72, mean age 79 (SD 6), female sex 40 (55%), mean SPPB 7.0 (SD 2.5)], median adherence was the same in both groups (76% vs. 76%; P = 0.99). Leucine did not improve the primary outcome [adjusted treatment effect 0.1 point (95%CI -1.0 to 1.1), P = 0.90]. No significant treatment benefit was seen for any secondary outcome including muscle mass [adjusted treatment effect -0.3 kg (95%CI -1.0 to 0.4), P = 0.47]. Meta-analysis of angiotensin converting enzyme inhibitor/angiotensin receptor blocker trials showed no clinically important treatment effect for the SPPB [between-group difference -0.1 points (95%CI -0.4 to 0.2)].Neither perindopril nor leucine improved physical performance or muscle mass in this trial; meta-analysis did not find evidence of efficacy of either ACE inhibitors or leucine as treatments to improve physical performance." @default.
• W4213065184 created "2022-02-24" @default.
• W4213065184 creator A5000572520 @default.
• W4213065184 creator A5002252858 @default.
• W4213065184 creator A5007277893 @default.
• W4213065184 creator A5008721117 @default.
• W4213065184 creator A5009232210 @default.
• W4213065184 creator A5009655769 @default.
• W4213065184 creator A5012254931 @default.
• W4213065184 creator A5013288717 @default.
• W4213065184 creator A5014057482 @default.
• W4213065184 creator A5014545439 @default.
• W4213065184 creator A5015146035 @default.
• W4213065184 creator A5015477612 @default.
• W4213065184 creator A5016105153 @default.
• W4213065184 creator A5017314948 @default.
• W4213065184 creator A5020237427 @default.
• W4213065184 creator A5020521035 @default.
• W4213065184 creator A5020963331 @default.
• W4213065184 creator A5021753470 @default.
• W4213065184 creator A5024717248 @default.
• W4213065184 creator A5027288528 @default.
• W4213065184 creator A5027516516 @default.
• W4213065184 creator A5044890844 @default.
• W4213065184 creator A5053794069 @default.
• W4213065184 creator A5058582219 @default.
• W4213065184 creator A5062166482 @default.
• W4213065184 creator A5065911417 @default.
• W4213065184 creator A5070050604 @default.
• W4213065184 creator A5070179242 @default.
• W4213065184 creator A5074227790 @default.
• W4213065184 creator A5075106701 @default.
• W4213065184 creator A5076608061 @default.
• W4213065184 creator A5077952215 @default.
• W4213065184 creator A5081409013 @default.
• W4213065184 creator A5084827019 @default.
• W4213065184 creator A5084884954 @default.
• W4213065184 creator A5088063654 @default.
• W4213065184 creator A5089468954 @default.
• W4213065184 creator A5090125318 @default.
• W4213065184 creator A9999999999 @default.
• W4213065184 date "2022-02-16" @default.
• W4213065184 modified "2023-10-08" @default.
• W4213065184 title "Effect of perindopril or leucine on physical performance in older people with sarcopenia: the LACE randomized controlled trial" @default.
• W4213065184 cites W1482694899 @default.
• W4213065184 cites W1603698970 @default.
• W4213065184 cites W1992803179 @default.
• W4213065184 cites W2000445173 @default.
• W4213065184 cites W2012485126 @default.
• W4213065184 cites W2054574324 @default.
• W4213065184 cites W2055082626 @default.
• W4213065184 cites W2055427232 @default.
• W4213065184 cites W2072278615 @default.
• W4213065184 cites W2096657471 @default.
• W4213065184 cites W2098039664 @default.
• W4213065184 cites W2102902846 @default.
• W4213065184 cites W2106956157 @default.
• W4213065184 cites W2110630734 @default.
• W4213065184 cites W2116294028 @default.
• W4213065184 cites W2117980765 @default.
• W4213065184 cites W2127835340 @default.
• W4213065184 cites W2130817102 @default.
• W4213065184 cites W2139035612 @default.
• W4213065184 cites W2149295929 @default.
• W4213065184 cites W2150042773 @default.
• W4213065184 cites W2159296038 @default.
• W4213065184 cites W2316138036 @default.
• W4213065184 cites W2607358094 @default.
• W4213065184 cites W2782016135 @default.
• W4213065184 cites W2782776573 @default.
• W4213065184 cites W2885145541 @default.
• W4213065184 cites W2894049215 @default.
• W4213065184 cites W2940158243 @default.
• W4213065184 cites W2941075934 @default.
• W4213065184 cites W2943413777 @default.
• W4213065184 cites W2965348904 @default.
• W4213065184 cites W2966890410 @default.
• W4213065184 cites W2980794190 @default.
• W4213065184 cites W2985792183 @default.
• W4213065184 cites W3013013531 @default.
• W4213065184 cites W3040737837 @default.
• W4213065184 cites W3044758221 @default.
• W4213065184 cites W3127744091 @default.
• W4213065184 cites W3133740619 @default.
• W4213065184 cites W3138591362 @default.
• W4213065184 cites W4200379278 @default.
• W4213065184 cites W4211144975 @default.
• W4213065184 cites W4213065184 @default.
• W4213065184 cites W819537267 @default.
• W4213065184 doi "https://doi.org/10.1002/jcsm.12934" @default.
• W4213065184 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35174663" @default.
• W4213065184 hasPublicationYear "2022" @default.
• W4213065184 type Work @default.
• W4213065184 citedByCount "9" @default.
• W4213065184 countsByYear W42130651842022 @default.
• W4213065184 countsByYear W42130651842023 @default.
• W4213065184 crossrefType "journal-article" @default.
• W4213065184 hasAuthorship W4213065184A5000572520 @default.

• next